Trevi Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing Haduvio, an oral extended-release formulation of nalbuphine, for treating chronic cough in patients with idiopathic pulmonary fibrosis, non-IPF interstitial lung disease, and refractory chronic cough. Haduvio acts as a kappa opioid receptor agonist and mu opioid receptor antagonist, targeting the cough reflex arc both centrally and peripherally to address nerve hypersensitivity underlying these conditions, where no approved therapies exist in the U.S. The company is advancing Haduvio through late-stage clinical trials, including positive Phase 2b results demonstrating statistically significant reductions in cough frequency. Trevi Therapeutics Inc. operates in the biotechnology sector, concentrating on neurologically mediated cardiorespiratory diseases that impose substantial burdens on patients, caregivers, and healthcare systems. Founded in 2011 and headquartered in New Haven, Connecticut, the company leverages its expertise in opioid receptor modulation to deliver novel investigational therapies for unmet medical needs in chronic cough management.